FeesSafety
Pluang+

Strategy promotes bitcoin as a global reserve asset with a detailed investment guide.

Market News
13 Sep 2026
Bitcoin
View Source
Bullish
Strategy promotes bitcoin as a global reserve asset with a detailed investment guide.

Strategy Inc., led by Michael Saylor, released a comprehensive bitcoin investor guide arguing that bitcoin could serve as a global reserve asset due to its fixed supply, independent verification, and global transferability. The guide explores various bitcoin investment forms, including direct ownership, funds, and corporate securities, each with distinct risks and legal implications. Strategy highlights bitcoin's scarcity as a key value driver but notes that demand and custody risks remain significant. The company holds a substantial bitcoin stake and envisions bitcoin competing alongside traditional financial assets by 2036.

More News

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...

Market News
Bullish
1 hour ago
CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...

Market News
Bullish
1 hour ago
CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...

Market News
Bullish
1 hour ago
Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...

Market News
Bullish
2 hours ago
Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App